Long-term efficacy and safety of paliperidone 6-month formulation: An open-label extension of a double-blind study in adult patients with schizophrenia

INTRODUCTION: Paliperidone palmitate 6-month (PP6M), administered twice-yearly, demonstrated non-inferiority to paliperidone palmitate 3-month (PP3M) in preventing relapse in patients with schizophrenia in a phase-3 randomized, double-blind (DB) global study.(1) We report results of a 2-year single-...

Descripción completa

Detalles Bibliográficos
Autores principales: Najarian, D., Turkoz, I., Galderisi, S., Lamaison, H. F., Zalitacz, P., Aravind, S., Richarz, U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595946/
http://dx.doi.org/10.1192/j.eurpsy.2023.345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595946/
http://dx.doi.org/10.1192/j.eurpsy.2023.345

Ejemplares similares